Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
5 "Kidney neoplasms"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Pediatric cancer
Epidemiologic and Clinical Outcomes of Pediatric Renal Tumors in Korea: A Retrospective Analysis of The Korean Pediatric Hematology and Oncology Group (KPHOG) Data
Kyung-Nam Koh, Jung Woo Han, Hyoung Soo Choi, Hyoung Jin Kang, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Kyung Taek Hong, Jung Yoon Choi, Sung Han Kang, Hyery Kim, Ho Joon Im, Seung Min Hahn, Chuhl Joo Lyu, Hee-Jo Baek, Hoon Kook, Kyung Mi Park, Eu Jeen Yang, Young Tak Lim, Seongkoo Kim, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Meerim Park, Hyeon Jin Park, Byung-Kiu Park, Jun Ah Lee, Jun Eun Park, Soon Ki Kim, Ji Yoon Kim, Hyo Sun Kim, Youngeun Ma, Kyung Duk Park, Sang Kyu Park, Eun Sil Park, Ye Jee Shim, Eun Sun Yoo, Kyung Ha Ryu, Jae Won Yoo, Yeon Jung Lim, Hoi Soo Yoon, Mee Jeong Lee, Jae Min Lee, In-Sang Jeon, Hye Lim Jung, Hee Won Chueh, Seunghyun Won, the Korean Pediatric Hematology and Oncology Group (KPHOG)
Cancer Res Treat. 2023;55(1):279-290.   Published online August 11, 2022
DOI: https://doi.org/10.4143/crt.2022.073
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Renal tumors account for approximately 7% of all childhood cancers. These include Wilms tumor (WT), clear cell sarcoma of the kidney (CCSK), malignant rhabdoid tumor of the kidney (MRTK), renal cell carcinoma (RCC), congenital mesoblastic nephroma (CMN) and other rare tumors. We investigated the epidemiology of pediatric renal tumors in Korea.
Materials and Methods
From January 2001 to December 2015, data of pediatric patients (0–18 years) newly-diagnosed with renal tumors at 26 hospitals were retrospectively analyzed.
Results
Among 439 patients (male, 240), the most common tumor was WT (n=342, 77.9%), followed by RCC (n=36, 8.2%), CCSK (n=24, 5.5%), MRTK (n=16, 3.6%), CMN (n=12, 2.7%), and others (n=9, 2.1%). Median age at diagnosis was 27.1 months (range 0-225.5) and median follow-up duration was 88.5 months (range 0-211.6). Overall, 32 patients died, of whom 17, 11, 1, and 3 died of relapse, progressive disease, second malignant neoplasm, and treatment-related mortality. Five-year overall survival and event free survival were 97.2% and 84.8% in WT, 90.6% and 82.1% in RCC, 81.1% and 63.6% in CCSK, 60.3% and 56.2% in MRTK, and 100% and 91.7% in CMN, respectively (p < 0.001).
Conclusion
The pediatric renal tumor types in Korea are similar to those previously reported in other countries. WT accounted for a large proportion and survival was excellent. Non-Wilms renal tumors included a variety of tumors and showed inferior outcome, especially MRTK. Further efforts are necessary to optimize the treatment and analyze the genetic characteristics of pediatric renal tumors in Korea.

Citations

Citations to this article as recorded by  
  • Congenital Mesoblastic Nephroma Mimic Wilms Tumor on 18F-FDG PET/CT and PET/MR
    Wenzhu Hu, Chunxia Qin, Fuqiang Shao, Mengting Li, Xiaoli Lan
    Clinical Nuclear Medicine.2024; 49(4): 353.     CrossRef
  • Progress towards Therapies for Solid Renal Tumors in Children
    洁 林
    Advances in Clinical Medicine.2024; 14(06): 245.     CrossRef
  • 6,984 View
  • 189 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
A Phage Display-Identified Peptide Selectively Binds to Kidney Injury Molecule-1 (KIM-1) and Detects KIM-1-Overexpressing Tumors in vivo
Md. Enamul Haque, Fatima Khan, Lianhua Chi, Smriti Gurung, Sri Murugan Poongkavithai Vadevoo, Rang-Woon Park, Dong-Kyu Kim, Sang Kyoon Kim, Byungheon Lee
Cancer Res Treat. 2019;51(3):861-875.   Published online October 1, 2018
DOI: https://doi.org/10.4143/crt.2018.214
AbstractAbstract PDFPubReaderePub
Purpose
This study was carried out to identify a peptide that selectively binds to kidney injury molecule-1 (KIM-1) by screening a phage-displayed peptide library and to use the peptide for the detection of KIM-1overexpressing tumors in vivo.
Materials and Methods
Biopanning of a phage-displayed peptide library was performed on KIM-1–coated plates. The binding of phage clones, peptides, and a peptide multimer to the KIM-1 protein and KIM-1–overexpressing and KIM-1–low expressing cells was examined by enzyme-linked immunosorbent assay, fluorometry, and flow cytometry. A biotin-peptide multimer was generated using NeutrAvidin. In vivo homing of the peptide to KIM-1–overexpressing and KIM1–low expressing tumors in mice was examined by whole-body fluorescence imaging.
Results
A phage clone displaying the CNWMINKEC peptide showed higher binding affinity to KIM-1 and KIM-1–overexpressing 769-P renal tumor cells compared to other phage clones selected after biopanning. The CNWMINKEC peptide and a NeutrAvidin/biotin-CNWMINKEC multimer selectively bound to KIM-1 over albumin and to KIM-1–overexpressing 769-P cells and A549 lung tumor cells compared to KIM-1-low expressing HEK293 normal cells. Co-localization and competition assays using an anti–KIM-1 antibody demonstrated that the binding of the CNWMINKEC peptide to 769-P cells was specifically mediated by KIM-1. The CNWMINKEC peptide was not cytotoxic to cells and was stable for up to 24 hours in the presence of serum. Whole-body fluorescence imaging demonstrated selective homing of the CNWM-INKEC peptide to KIM-1–overexpressing A498 renal tumor compared to KIM1–low expressing HepG2 liver tumor in mice.
Conclusion
The CNWMINKEC peptide is a promising probe for in vivo imaging and detection of KIM-1‒overexpressing tumors.

Citations

Citations to this article as recorded by  
  • Bi-functional KIT-PR1P peptides combine with VEGF to protect ischemic kidney in rats by targeting to Kim-1
    Runxue Zhou, Hang Liu, Xianglin Hou, Qi Liu, Shuwei Sun, Xiaoge Li, Wenxuan Cao, Weihong Nie, Chunying Shi, Wei Chen
    Regenerative Therapy.2024; 25: 162.     CrossRef
  • Improving Pharmacokinetics of Peptides Using Phage Display
    Mallika Asar, Jessica Newton-Northup, Mette Soendergaard
    Viruses.2024; 16(4): 570.     CrossRef
  • Unveiling Invisible Extracellular Vesicles: Cutting‐Edge Technologies for Their in Vivo Visualization
    Prakash Gangadaran, Fatima Khan, Ramya Lakshmi Rajendran, Akanksha Onkar, Anshika Goenka, Byeong‐Cheol Ahn
    WIREs Nanomedicine and Nanobiotechnology.2024;[Epub]     CrossRef
  • Modified Bacteriophage for Tumor Detection and Targeted Therapy
    Yuanzhao Shen, Jingyu Wang, Yuting Li, Chih-Tsung Yang, Xin Zhou
    Nanomaterials.2023; 13(4): 665.     CrossRef
  • Tumor microenvironment signaling and therapeutics in cancer progression
    Anshika Goenka, Fatima Khan, Bhupender Verma, Priyanka Sinha, Crismita C. Dmello, Manasi P. Jogalekar, Prakash Gangadaran, Byeong‐Cheol Ahn
    Cancer Communications.2023; 43(5): 525.     CrossRef
  • Specific bFGF targeting of KIM-1 in ischemic kidneys protects against renal ischemia-reperfusion injury in rats
    Siqi Song, Xianglin Hou, Weiwei Zhang, Xinyu Liu, Wei Wang, Xiaoya Wang, Wenxuan Cao, Yujun Xia, Wei Chen, Chunying Shi
    Regenerative Biomaterials.2022;[Epub]     CrossRef
  • Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy
    Chunyan Li, Jia Li, Ying Xu, Ying Zhan, Yu Li, Tingting Song, Jiao Zheng, Hong Yang
    International Journal of Peptide Research and Therapeutics.2021; 27(1): 587.     CrossRef
  • Detection of kidney disease biomarkers based on fluorescence technology
    Bicheng Yao, Marie-Claire Giel, Yuning Hong
    Materials Chemistry Frontiers.2021; 5(5): 2124.     CrossRef
  • Screening and Identification of a Specific Binding Peptide to Ovarian Cancer Cells from a Phage-Displayed Peptide Library
    Shuhui Zhao, Chunyan Li, Yunge Gao, Luomeng Qian, Jian Dong, Lianghao Zhai, Biliang Chen, Jianfang Zhang
    International Journal of Peptide Research and Therapeutics.2021; 27(3): 1741.     CrossRef
  • 10,412 View
  • 393 Download
  • 11 Web of Science
  • 9 Crossref
Close layer
Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors Who Underwent Curative Surgery Only for Prostate, Kidney and Bladder Cancer: Comparison among Survivors and with the General Population
Dong Wook Shin, Hyun Sik Park, Sang Hyub Lee, Seung Hyun Jeon, Seok Cho, Seok Ho Kang, Seung Chol Park, Jong Hyock Park, Jinsung Park
Cancer Res Treat. 2019;51(1):289-299.   Published online May 4, 2018
DOI: https://doi.org/10.4143/crt.2018.053
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to compare health-related quality of life (HRQoL) of disease-free prostate (PC), kidney (KC), and bladder cancer (BC) survivors with that of the general population.
Materials and Methods
Our study included 331 urological cancer (UC) survivors (114 PC, 108 KC, and 109 BC) aged ≥ 50 years disease-free for at least 1 year after surgery. The control group included 1,177 subjects without a history of cancer. The HRQoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30, the Duke-UNC Functional Social Support Questionnaire, and the Patient Health Questionnaire-9.
Results
There was no significant difference between the groups in terms of any of the functioning sub-scales and symptoms, except significantly lower social functioning observed in BC survivors than that observed in KC survivors. Although the three groups of UC survivors showed essentially similar functioning sub-scales and symptoms when compared to the general population, PC and BC survivors showed significantly lower social functioning and a lower appetite than that observed in controls. KC survivors showed lower physical functioning, as well as higher pain and dyspnea. Although all three groups of UC survivors reported higher financial difficulties, they also reported higher perceived social support than that reported by the non-cancer control group. No statistically significant difference was observed in terms of depressive symptoms between each group of UC survivors and the general population.
Conclusion
Disease-free survivors of the three major types of UCs showed generally similar HRQoL compared to the general population, as well as compared to each other.

Citations

Citations to this article as recorded by  
  • Role performance and factors affecting quality of life in bladder cancer survivors with ileal orthotopic neobladder
    So Hee Kim, Eunjung Ryu, Byong Chang Jeong
    Asia-Pacific Journal of Oncology Nursing.2024; 11(6): 100490.     CrossRef
  • The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score‐matched study
    Giuseppe Palermo, Francesco Pio Bizzarri, Eros Scarciglia, Emilio Sacco, Koosha Moosavi Seyed, Pierluigi Russo, Filippo Gavi, Battista Filomena Giovanni, Francesco Rossi, Marco Campetella, Angelo Totaro, Nazario Foschi, Marco Racioppi
    International Journal of Urology.2024; 31(12): 1423.     CrossRef
  • Factors Affecting the Health-Related Quality of Life of Patients with Bladder Cancer
    Haetsal Kwon, Hyojung Park
    Journal of Korean Public Health Nursing.2024; 38(3): 358.     CrossRef
  • Properties of the Shift and Persist Questionnaire in adolescent and young adult cancer patients and survivors: Validity, consistency, and interpretability
    Karly M. Murphy, Edith Chen, Edward H. Ip, Abby R. Rosenberg, Mallory A. Snyder, John M. Salsman
    Quality of Life Research.2023; 32(1): 273.     CrossRef
  • Adoption of patient communication rules in clinical practice and the role of faith-based communities in shaping them: the palliative aspect of spiritual support
    Konstantin Sokolovskiy, Olga Pashanova, Vladimir Beketov, Andrey Aleshkin
    Mental Health, Religion & Culture.2023; 26(1): 16.     CrossRef
  • Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review
    Amy O’Dea, Craig Gedye, Belinda Jago, Catherine Paterson
    Journal of Cancer Survivorship.2022; 16(6): 1279.     CrossRef
  • Mental Health in Urologic Oncology
    Danyon Anderson, Abrahim N. Razzak, Matthew McDonald, David Cao, Jamal Hasoon, Omar Viswanath, Alan D. Kaye, Ivan Urits
    Health Psychology Research.2022;[Epub]     CrossRef
  • Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review
    Liliana Vartolomei, Manuela Schmidinger, Mihai Vartolomei, Shahrokh Shariat
    Journal of Clinical Medicine.2022; 11(21): 6383.     CrossRef
  • Health-Related Quality of Life among Cancer Survivors Depending on the Occupational Status
    Kisook Kim, Hyohyeon Yoon
    International Journal of Environmental Research and Public Health.2021; 18(7): 3803.     CrossRef
  • Feasibility of a socio-spiritual intervention to improve quality of life of adult Nigerians with cancer and their family caregivers: Protocol for a randomised controlled trial
    Israel Gabriel, Debra Creedy, Elisabeth Coyne
    Contemporary Clinical Trials Communications.2021; 22: 100802.     CrossRef
  • Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls—results from a population-based study
    Salome Adam, Daniela Doege, Lena Koch-Gallenkamp, Melissa S. Y. Thong, Heike Bertram, Andrea Eberle, Bernd Holleczek, Ron Pritzkuleit, Mechthild Waldeyer-Sauerland, Annika Waldmann, Sylke Ruth Zeissig, Lina Jansen, Sabine Rohrmann, Hermann Brenner, Volker
    Supportive Care in Cancer.2020; 28(6): 2875.     CrossRef
  • Comorbid depression in medical diseases
    Stefan M. Gold, Ole Köhler-Forsberg, Rona Moss-Morris, Anja Mehnert, J. Jaime Miranda, Monika Bullinger, Andrew Steptoe, Mary A. Whooley, Christian Otte
    Nature Reviews Disease Primers.2020;[Epub]     CrossRef
  • Health-related Quality of Life and Its Related Factors among Cancer Survivors and General Adults: Focusing on Lifestyle Behaviors and Mental Health
    Eun A Song, Youngran Kweon, Yoon Young Hwang, Minjeong An
    Korean Journal of Adult Nursing.2020; 32(4): 385.     CrossRef
  • Age and gender differences in anxiety and depression in cancer patients compared with the general population
    Andreas Hinz, Philipp Yorck Herzberg, Florian Lordick, Joachim Weis, Hermann Faller, Elmar Brähler, Martin Härter, Karl Wegscheider, Kristina Geue, Anja Mehnert
    European Journal of Cancer Care.2019;[Epub]     CrossRef
  • 12,108 View
  • 216 Download
  • 12 Web of Science
  • 14 Crossref
Close layer
Effects of Aspirin, Nonsteroidal Anti-inflammatory Drugs, Statin, and COX2 Inhibitor on the Developments of Urological Malignancies: A Population-Based Study with 10-Year Follow-up Data in Korea
Minyong Kang, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Chang Wook Jeong
Cancer Res Treat. 2018;50(3):984-991.   Published online October 27, 2017
DOI: https://doi.org/10.4143/crt.2017.248
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to determine the impact of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), statin, and cyclooxygenase 2 (COX-2) inhibitor on the development of kidney, prostate, and urothelial cancers by analyzing the Korean National Health Insurance Service–National Sample Cohort (NHIS-NSC) database.
Materials and Methods
Among a representative sample cohort of 1,025,340 participants in NHIS-NSC database in 2002, we extracted data of 799,850 individuals who visited the hospital more than once, and finally included 321,122 individuals aged 40 and older. Following a 1-year washout period between 2002 and 2003, we analyzed 143,870 (male), 320,861 and 320,613 individuals for evaluating the risk of prostate cancer, kidney cancer and urothelial cancer developments, respectively, during 10-year follow-up periods between 2004 and 2013. The medication group consisted of patients prescribed these drugs more than 60% of the time in 2003. To adjustfor various parameters of the patients, a multivariate Cox regression model was adopted.
Results
During 10-year follow-up periods between 2004 and 2013, 9,627 (6.7%), 1,107 (0.4%), and 2,121 (0.7%) patients were diagnosed with prostate cancer, kidney cancer, and urothelial cancer, respectively. Notably, multivariate analyses revealed that NSAIDs significantly increased the risk of prostate cancer (hazard ratio [HR], 1.35). Also, it was found that aspirin (HR, 1.28) and statin (HR, 1.55) elevated the risk of kidney cancer. No drugs were associated with the risk of urothelial cancer.
Conclusion
In sum, our study provides the valuable information for the impact of aspirin, NSAID, statin, and COX-2 inhibitor on the risk of prostate, kidney, and urothelial cancer development and its survival outcomes.

Citations

Citations to this article as recorded by  
  • Association between Statin Use and Clinical Outcomes in Patients with De Novo Metastatic Prostate Cancer: A Propensity Score-weighted Analysis
    Tzu Shuang Chen, Hui Ying Liu, Yin Lun Chang, Yao Chi Chuang, Yen Ta Chen, Yu Li Su, Chun Chieh Huang, Yen Ting Wu, Hung Jen Wang, Hao Lun Luo
    The World Journal of Men's Health.2024; 42(3): 630.     CrossRef
  • Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database
    Gyoohwan Jung, Jung Kwon Kim, Seong Soo Jeon, Jae Hoon Chung, Cheol Kwak, Chang Wook Jeong, Hanjong Ahn, Jae Young Joung, Tae Gyun Kwon, Sung Woo Park, Seok-Soo Byun
    The World Journal of Men's Health.2023; 41(1): 110.     CrossRef
  • Evaluation of statin use and renal cell carcinoma risk identifies sex-specific associations with RCC subtypes
    Irmina Maria Michalek, Rebecca E. Graff, Alejandro Sanchez, Toni K. Choueiri, Eunyoung Cho, Mark A. Preston, Kathryn M. Wilson
    Acta Oncologica.2023; 62(9): 988.     CrossRef
  • Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies
    Shaodi Ma, Weihang Xia, Birong Wu, Chenyu Sun, Yuemeng Jiang, Haixia Liu, Scott Lowe, Zhen Zhou, Peng Xie, Juan Gao, Linya Feng, Xianwei Guo, Guangbo Qu, Yehuan Sun
    European Journal of Clinical Pharmacology.2023; 79(11): 1475.     CrossRef
  • Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review
    Hwanik Kim, Jung Kwon Kim
    The World Journal of Men's Health.2022; 40(3): 412.     CrossRef
  • The Association of Prediagnostic Statin Use with Aggressive Prostate Cancer from the Multiethnic Cohort Study
    Fei Chen, Peggy Wan, Lynne R. Wilkens, Loïc Le Marchand, Christopher A. Haiman
    Cancer Epidemiology, Biomarkers & Prevention.2022; 31(5): 999.     CrossRef
  • Aspirin and the risk of nondigestive tract cancers: An updated meta‐analysis to 2019
    Claudia Santucci, Silvano Gallus, Marco Martinetti, Carlo La Vecchia, Cristina Bosetti
    International Journal of Cancer.2021; 148(6): 1372.     CrossRef
  • Association between depression and risk of Parkinson's disease in South Korean adults
    Wonjeong Jeong, Hyunkyu Kim, Jae Hong Joo, Sung-In Jang, Eun-Cheol Park
    Journal of Affective Disorders.2021; 292: 75.     CrossRef
  • Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment
    Bo Fan, Alradhi Mohammed, Yuanbin Huang, Hong Luo, Hongxian Zhang, Shenghua Tao, Weijiao Xu, Qian Liu, Tao He, Huidan Jin, Mengfan Sun, Man Sun, Zhifei Yun, Rui Zhao, Guoyu Wu, Xiancheng Li
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study
    Luyang Liu, Chao Sheng, Zhangyan Lyu, Hongji Dai, Kexin Chen
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study
    Charlotte Skriver, Christian Dehlendorff, Michael Borre, Klaus Brasso, Signe Benzon Larsen, Anne Tjønneland, Anton Pottegård, Jesper Hallas, Henrik Toft Sørensen, Søren Friis
    Cancer Causes & Control.2020; 31(2): 139.     CrossRef
  • Impact of Concomitant Medication Use and Immune-Related Adverse Events on Response to Immune Checkpoint Inhibitors
    Shipra Gandhi, Manu Pandey, Nischala Ammannagari, Chong Wang, Mark J Bucsek, Lamya Hamad, Elizabeth Repasky, Marc S Ernstoff
    Immunotherapy.2020; 12(2): 141.     CrossRef
  • Risks of solid cancers in elderly persons with osteoarthritis or ankylosing spondylitis
    Michael M Ward, Sara Alehashemi
    Rheumatology.2020; 59(12): 3817.     CrossRef
  • Complex roles of the old drug aspirin in cancer chemoprevention and therapy
    Hui Hua, Hongying Zhang, Qingbin Kong, Jiao Wang, Yangfu Jiang
    Medicinal Research Reviews.2019; 39(1): 114.     CrossRef
  • Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform
    Chang Wook Jeong, Jungyo Suh, Hyeong Dong Yuk, Bum Sik Tae, Miso Kim, Bhumsuk Keam, Jin Ho Kim, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim, Kyung Chul Moon, Gi Jeong Cheon, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak
    Investigative and Clinical Urology.2019; 60(4): 235.     CrossRef
  • The impact of acute inflammation on progression and metastasis in pancreatic cancer animal model
    Keun Soo Ahn, Ji Yeon Hwang, Ho-Seong Han, Sang Tae Kim, Ilseon Hwang, Young-Ok Chun
    Surgical Oncology.2018; 27(1): 61.     CrossRef
  • Prostate cancer multifocality, the index lesion, and the microenvironment
    Rafael R. Tourinho-Barbosa, Jean de la Rosette, Rafael Sanchez-Salas
    Current Opinion in Urology.2018; 28(6): 499.     CrossRef
  • Intake of Non-steroidal Anti-inflammatory Drugs and the Risk of Prostate Cancer: A Meta-Analysis
    Zhenhua Shang, Xue Wang, Hao Yan, Bo Cui, Qi Wang, Jiangtao Wu, Xin Cui, Jin Li, Tongwen Ou, Kun Yang
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • 11,286 View
  • 330 Download
  • 17 Web of Science
  • 18 Crossref
Close layer
Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience
Che Ry Hong, Hyoung Jin Kang, Hee Young Ju, Ji Won Lee, Hyery Kim, Sung-Hye Park, Il Han Kim, Kyung Duk Park, Hee Young Shin
Cancer Res Treat. 2015;47(4):889-896.   Published online January 2, 2015
DOI: https://doi.org/10.4143/crt.2013.176
AbstractAbstract PDFPubReaderePub
Purpose
Malignant rhabdoid tumor (MRT) is a rare and highly aggressive tumor that affects young children. Due to its extreme rarity, most of the available data are based on retrospective case series. To add to the current knowledge of this disease, we reviewed the patients treated for extra-cranial MRT in our institute. Materials and Methods A retrospective medical record review was conducted on children treated for pathologically confirmed extra-cranial MRT at Seoul National University Children’s Hospital between January 2003 and May 2013. Results Eleven patients (7 boys, 4 girls) were diagnosed with extra-cranial MRT at a median age of 9 months old. INI1 staining was important in the pathological confirmation. Six patients (55%) had renal MRT and five (45%) had soft tissue MRT. Five patients (45%) had metastases at diagnosis. All patients underwent chemotherapy, eight patients (73%) underwent surgery, six patients (55%) received therapeutic radiotherapy, and four patients (36%) underwent high dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) with melphalan, etoposide, and carboplatin. Five patients (45%) died of disease following progression (n=3) or relapse (n=2), however, there was no treatment related mortality. The overall survival of the cohort was 53.0% and the event-free survival was 54.5% with a median follow-up duration of 17.8 months (range, 2.3 to 112.3 months). Conclusion Extra-cranial MRT is still a highly aggressive tumor in young children. However, the improved survival of our cohort is promising and HDCT/ASCR with melphalan, etoposide, and carboplatin may be a promising treatment option.

Citations

Citations to this article as recorded by  
  • Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach
    Siqi Xie, Yuanyuan Fang, Yingying Yang, Lan Liu, Jianxi Bai, Sheng Lin, Bing Zhang, Yifan Fang
    European Journal of Pediatrics.2023; 183(2): 557.     CrossRef
  • Infantile Extracranial Rhabdoid Tumor of the Scalp
    Sura Al Rawabdeh, Deifallah Alsharari, Hayat Khasawneh, Ola M. Al Waqfi, Qamar Yaser Malabeh, Hiathem Abu Alhaija, Raed Mohammad Aljubour, Hamzeh M. Alkhawaldeh, Pablo Fernandez Pe as
    Case Reports in Medicine.2021; 2021: 1.     CrossRef
  • Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing
    Che Ry Hong, Hyoung Jin Kang, Seol Ju Moon, Jaeseong Oh, Kyung Taek Hong, Jung Yoon Choi, Kyung-Sang Yu, Hee Young Shin
    Bone Marrow Transplantation.2020; 55(1): 137.     CrossRef
  • Successful Treatment of Extra‐Renal Noncerebral Rhabdoid Tumors with VIDE
    Naoko Yasui, Akihiko Yoshida, Eisuke Kobayashi, Fumihiko Nakatani, Hiroshi Kawamoto
    Pediatric Blood & Cancer.2016; 63(2): 352.     CrossRef
  • 14,592 View
  • 149 Download
  • 5 Web of Science
  • 4 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP